Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly — Stella

Home/Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)/

View on ClinicalTrials.gov

Recruiting

Back to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

Russia

Tyumen State Medical University, Tyumen, Tyumen Oblast

Key details

Sponsor

Phenomen Pharma

Enrollment target

~90 participants

Started

June 2025

Primary completion

July 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 65 Years

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.